Page 86 - Annual Report
P. 86

HONG KONG ACADEMY OF MEDICINE
               香 港 醫 學 專 科 學 院
               香港醫學專科學院
               NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
               FOR THE YEAR ENDED 31 DECEMBER 2023



               2.   BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)

                   h)   Other financial assets

                        Investments other than equity investments

                        Non-equity investments held by the Academy are classified as fair value through profit or loss
                        (FVTPL) when the contractual cash flows of the investment do not represent solely payments of
                        principal  and  interest.  Changes  in  the  fair  value  of  the  investment  (including  interest)  are
                        recognised in profit or loss.

                        Equity investments

                        An investment in equity securities is classified as financial assets at FVTPL unless the equity
                        investment  is  not  held  for  trading  purposes  and  on  initial  recognition  of  the  investment  the
                        Academy makes an irrevocable election to designate the investment at fair value through other
                        comprehensive income (FVTOCI) (non-recycling) such that subsequent changes in fair value
                        are  recognised  in  other  comprehensive  income.  Such  elections  are  made  on  an
                        instrument-by-instrument basis, but may only be made if the investment meets the definition of
                        equity from the issuer’s perspective. Where such an election is made, the amount accumulated
                        in  other  comprehensive  income  remains  in  the  fair  value  reserve  (non-recycling)  until  the
                        investment is disposed of. At the time of disposal, the attributable amount accumulated in the
                        fair value reserve (non-recycling) is transferred to general fund. It is not recycled through profit
                        or loss.

                        Dividends from an investment in equity securities, irrespective of whether classified as at FVTPL
                        or FVTOCI, are recognised in profit or loss as other income in accordance with the policy set out
                        in note 2(n).

                   i)   Receivables

                        Receivables are initially recognised at fair value and thereafter stated at amortised cost using
                        the effective interest method, less allowance for impairment of doubtful debts (see note 2(g)(i)),
                        except where the receivables are interest-free loans made to related parties without any fixed
                        repayment  terms  or  the  effect  of  discounting  would  be  immaterial.  In  such  cases,  the
                        receivables are stated at cost less allowance for impairment of doubtful debts.

                        Receivables are stated at amoritised cost using the effective interest method less allowance for
                        credit losses (see note 2(g)).

                   j)   Payables

                        Payables are initially recognised at fair value and thereafter stated at amortised cost unless the
                        effect of discounting would be immaterial, in which case they are stated at cost.

                   k)   Cash and cash equivalents

                        Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks
                        and  other  financial  institutions,  and  short-term,  highly  liquid  investments  that  are  readily
                        convertible into known amounts of cash and which are subject to an insignificant risk of changes
                        in value, having been within three months of maturity at a acquisition.




                                                            17
                                                            17

     84          HKAM Annual Report 2024
   81   82   83   84   85   86   87   88   89   90   91